Mr. Johnson is a recognized biopharma executive leader in the industry with more than three decades of experience across corporate strategy, operations, investing, clinical development, and oncology drug commercialization. He most recently served as Executive Chairman at Applied Therapeutics, a company focused on developing transformative treatments for rare disease. Mr. Johnson also previously was the Chief Executive Officer of Reaction Biology, a global Contract Research Organization. Prior to that he was the Chief Executive Officer of Stonebridge Biopharma prior to its merger with Xeris Biopharma. Mr. Johnson has held executive management roles at leading global corporations, including Johnson & Johnson, where he spent the majority of his career and served as the Company Group Chairman of Biopharmaceuticals within Johnson & Johnson. He was responsible for Johnson & Johnson Biotechnology, Immunology and Oncology commercial businesses. Mr. Johnson also served as President of Eli Lilly & Company’s Worldwide Oncology unit, following the company’s 2008 acquisition of Imclone Systems, Inc., where he served as Chief Executive Officer and a member of Imclone’s Board of Directors.
 

Mr. Johnson has served on 19 boards and presently serves on the boards of Reaction Biology, Axogen (AXGN), Xeris Pharmaceuticals (XERS), and Verastem Oncology (VSTM). He served on two private equity backed company boards through successful exits. He has also served as a member of the board of directors of Pharmaceutical Research and Manufacturers of America (PhRMA) and as a member of the Health Section Governing Board of Biotechnology Industry Organization (BIO).

Dr. Bunn is a Distinguished Professor of Medicine and James Dudley Chair in Cancer Research, Division of Medical Oncology at the University of Colorado School of Medicine. Dr. Bunn previously served as section head of the U.S. National Cancer Institute (NCI)-Navy Medical Oncology branch, Head of the Division of Medical Oncology at the University of Colorado, and Director of the University of Colorado Cancer Center.
 

Dr. Bunn was President of the American Society of Clinical Oncology (ASCO), as well as on its Board of Directors. He was also President of the American Association of Cancer Institutes (AACI) and has chaired the U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee. Dr. Bunn served on the Board of Directors, as President and as Chief Executive Officer, of the International Association for the Study of Lung Cancer (IASLC), growing the IASLC to become a highly impactful, multidisciplinary organization that includes researchers and clinicians from all over the world.
 

Dr. Bunn was also the Principal Investigator on the Specialized Program in Research Excellence in Lung Cancer (SPORE) grant funded by NCI to expand understanding about the biology of the disease, as well as to find new methods of diagnosis, prevention, and treatment. The author of hundreds of articles, reviews and book chapters, Dr. Bunn’s work is credited with setting standards in the treatment of the disease.

Mr. Gagnon has more than 20 years of business, commercial, and global financial operations experience and currently serves as Chief Financial Officer of Opus Genetics, a publicly held biotechnology company developing therapies of transformative gene therapies for the treatment of inherited retinal diseases.
 

Prior to that, Mr. Gagnon was Chief Financial Officer of Remix Therapeutics, a privately held biotechnology company developing therapies to modulate RNA processing, previously Chief Financial Officer / Operating Partner of Gurnet Point Capital, a healthcare venture capital and private equity fund, and Chief Financial Officer of Verastem Oncology. Before joining Verastem in 2018, Mr. Gagnon served as the Chief Financial Officer at Harvard Bioscience, Inc., Executive Vice President, Chief Financial Officer and Treasurer at Clean Harbors, Inc., as well as Chief Accounting Officer and Controller at Biogen Idec, Inc. Earlier, he worked in a variety of senior positions at Deloitte & Touche, LLP, and Price Waterhouse Coopers, LLP.
 

Mr. Gagnon holds a Master of Business Administration from the MIT Sloan School of Management and a Bachelor of Arts in Accounting from Bentley College.
 

Mr. Kapur is a deeply experienced executive with over 25 years of experience in pharmaceutical and biotech companies across U.S. and international markets. He has held senior leadership positions where he has been responsible for launching significant global brands, building and managing commercial capabilities in small and large organizations, driving corporate strategy, and managing alliances.
 

Mr. Kapur is currently a member of the Board of Directors for Nurix Therapeutics. Most recently, he served as the Executive Vice President, Corporate Strategy and Chief Commercial Officer at Geron Corporation. Before Geron, Mr. Kapur served as the Chief Commercial Officer at Actinium Pharmaceuticals, Inc. and as the Vice President, Head of Early Assets, Biomarkers and External Innovation for Worldwide Oncology Commercialization at Bristol-Myers Squibb. Previously, Mr. Kapur was Vice President, Global Head of Commercial and Portfolio Strategy at Baxalta, Inc., which was acquired by Shire PLC in 2016. Before joining Baxalta, Mr. Kapur served as the Vice President, Commercial Leader Hematology Franchise at Johnson & Johnson’s global pharmaceutical strategy organization and in various sales and marketing leadership roles.
 

Mr. Kapur holds a Bachelor of Engineering from Birla Institute of Technology in India, a Master of Science in Industrial Engineering from Louisiana Tech University, and a Master of Business Administration from the Fuqua School of Business at Duke University.

Dr. Kauffman joined Verastem Oncology in December 2025 as President of Development after serving as the Company’s Lead Director of Verastem’s Board of Directors since June 2016. Dr. Kauffman has a deep understanding of the Company’s strategy, clinical development plans, and operations.
 

Previously, Dr. Kauffman served as the Chief Executive Officer of Nereid Therapeutics. He was co-founder and Chief Executive Officer of Karyopharm, where he guided the Company’s transition from a discovery stage biotechnology company to a commercial stage organization and the global approvals of XPOVIO®. Prior to co-founding Karyopharm, Dr. Kauffman was Chief Medical Officer of Onyx Pharma, where he led the development of Kyprolis® following the Onyx acquisition of Proteolix Inc., where he served as a board member and then Chief Medical Officer. Previously, Dr. Kauffman was President and Chief Executive Officer of EPIX Pharmaceuticals, Inc. (previously Predix Pharmaceuticals, Inc.). Before that, he was the leader of the Velcade® development program at Millennium Pharmaceuticals. He also held a number of senior positions at Millennium Predictive Medicine and Biogen Inc.
 

Dr. Kauffman received his M.D. and Ph.D. from Johns Hopkins Medical School, trained in Internal Medicine at Beth Israel (Deaconess) Medical Center and in Rheumatology at Massachusetts General Hospital, and is board certified in Internal Medicine.

Mr. Paterson was appointed President and Chief Executive Officer of Verastem Oncology in 2023, following more than a decade of increasing leadership roles and responsibilities within the Company since joining in 2011. He has more than 30 years of experience across oncology drug and diagnostic development, business development, and launch planning.
 

Before joining Verastem, Mr. Paterson was the co-founder and Chief Operating Officer of On-Q-ity, a developer of technology to capture and analyze circulating tumor cells, and the founding Chief Executive Officer of The DNA Repair Company (merged to form On-Q-ity), which developed oncology-focused molecular diagnostics. Prior to that, Mr. Paterson was Head of Global Strategy for Specialty Market and Patient-Level Data at IMS Health, after playing a key role in the acquisition of PharMetrics by IMS Health as Vice President, Marketing and Corporate Development. While at PharMetrics, Mr. Paterson led the development of an innovative suite of pharmaceutical product launch tools that became the basis of the company’s product line. Earlier in his career, Mr. Paterson led clinical development and regulatory initiatives in academic, industry, and Contract Research Organizations.
 

Mr. Paterson holds a Bachelor of Arts in Biology from Boston University and attended the Northeastern University Graduate Pharmacology program.

Ms. Robertson is the Executive Vice President and Chief Financial Officer of Geron Corporation. Prior to joining Geron Corporation, she served as the Chief Financial Officer of Editas Medicine, a CRISPR genome editing company, where she raised $500M in capital to support the Company’s research transition into late-stage clinical development. Before that, she served as Chief Financial Officer of Momenta Pharmaceuticals, from 2018 until 2020, leading the finance team through a strategic restructuring, before its acquisition by Johnson & Johnson.
 

Prior to joining Momenta, Ms. Robertson held multiple commercial finance roles of increasing responsibility, including Vice President, Oncology Finance for Baxalta following its spin-off from Baxter International where she worked on the acquisition and commercialization of their first oncology drug, Oncaspar® and Head of Financial Planning and Analysis and Operations Excellence at Ironwood Pharmaceuticals, positioning the finance organization to support the commercial launch of Linzess®. Before that, for 16 years, she held various finance and commercial operations roles at Genzyme Corporation (now Sanofi Genzyme) where she led the integration of several acquired oncology assets, subsequently leading the buildout of the commercial operations team to support five global commercial products.
 

Ms. Robertson received her Bachelor of Science in Finance and Associate of Science in Accounting and Management from Bentley University.

Dr. Rowinsky’s professional focus has been on the clinical and registrational strategies of anticancer therapeutics. Currently, Dr. Rowinsky serves as a Director and President at Inspirna, Inc (formerly RGenix, Inc,) a life sciences company focused on discovering new cancer targets using a novel microRNA platform licensed. He served as a Consulting Chief Medical Officer for Hummingbird Biosciences, which has a novel platform for the unique epitope targeting of monoclonal antibodies from February 2020 to March 2023, and also served as the Chief Scientific Officer of Clearpath Development Co, which rapidly advanced development-stage therapeutic assets to pre-defined human proof-of-concept milestones.
 

Prior to serving in these capacities, he was the Head of Research and Development, Chief Medical Officer, and Executive Vice President of Stemline Therapeutics (2010-2015). In 2010, Dr. Rowinsky co-founded Primrose Therapeutics and became its Chief Executive Officer until it was acquired in 2011. From 2005 to 2010, he served as the Chief Medical Officer and Executive Vice President of Clinical Development and Regulatory Affairs of ImClone Systems Incorporated, a life sciences company focused on monoclonal antibodies, which was acquired by Eli Lilly and Company. Before that, Dr. Rowinsky held several positions at the Cancer Therapy and Research Center’s Institute of Drug Development, including Director of the Institute and SBC Endowed Chair for Early Drug Development. Prior to that, he served as Clinical Professor of Medicine in the Division of Medical Oncology at the University of Texas Health Science Center at San Antonio and as Associate Professor of Oncology at the Johns Hopkins University School of Medicine.
 

Dr. Rowinsky is a member of the Board of Directors of Biogen and Purple Biotech, all public life sciences companies, and has served on the Board of Directors of BIND Therapeutics, a life sciences company acquired by Pfizer, and Navidea Biopharmaceuticals, Inc. He played an integral role in the development and execution of clinical development and registrational strategies resulting in the approval of a wide array of classical cytotoxics, monoclonal antibodies, and targeted therapeutics worldwide. He has authored more than 310 peer-reviewed manuscripts and serves as an editor of several cancer journals.

Mr. Stuglik served as the Chief Executive Officer of Verastem Oncology from 2019 through 2023. He is a global leader in the oncology pharmaceutical sector, having successfully developed, acquired, and launched several important oncology products across multiple tumor types and therapeutic approaches in his more than 30-year career in U.S. and international pharmaceutical development, product strategy, commercialization, and business development. He spent the majority of his career at Eli Lilly and Company, culminating in his role as Global Vice President and Chief Marketing Officer, Oncology Global Marketing, advancing Lilly Oncology from a single approved product to a portfolio of marketed or late-stage compounds across more than 10 cancer types.
 

He was a founding member of Proventus Health Solutions, assisting biotech companies integrate development and commercial considerations into a unified approach. He is a member of the Board of Directors for Verastem Oncology (VSTM), Oncopeptides AB (ONCO), and Puma Biotechnology, Inc (PBYI). Mr. Stuglik earned his Bachelor of Science in Pharmacy from Purdue University and holds memberships in the American Society of Clinical Oncology, the American Association for Cancer Research, and the International Association for the Study of Lung Cancer.

Dr. Tollefson is the Chief Oncology Medical Officer at Pfizer. Previously, Dr. Tollefson served as the Senior Vice President and Head of Global Medical Affairs at Seagen Inc., where she has led the medical organization through the successful launches of three practice-changing medicines and established a global medical affairs organization.
 

Dr. Tollefson has 30 years of experience in the pharmaceutical industry, spending much of her early career at Eli Lilly and Company serving in progressive leadership roles in clinical operations, clinical development, portfolio & program management, and global medical affairs. She supported Lilly’s acquisition and integration of ImClone Systems in 2008 and was part of the Oncology Business Unit Leadership team until her retirement in 2017.
 

During her career she has been involved in the launch of eight new medicines and numerous additional indications in the U.S. and international markets, serving patients in over 10 tumor and therapeutic areas. Dr. Tollefson has served on the philanthropic boards of the American Lung Association and the Leukemia and Lymphoma Society Indiana Board of Trustees. She started her undergraduate studies at Kansas State University and earned her Doctor of Pharmacy from the University of Kansas.